Developer docs
API playgroundTry for free, no card

Search company profiles

Nyxoah

Full company profile

uuid00003v5

Namestring
Nyxoah
Legal namestring
Nyxoah SA
Websiteurl
nyxoah.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Nyxoah SA is a Belgian medical technology company that develops and commercializes the Genio system, a bilateral hypoglossal nerve stimulation (HGNS) therapy for moderate-to-severe obstructive sleep apnea (OSA) in adults who have failed, refused, or cannot tolerate CPAP. The system consists of a battery-free, leadless implantable neurostimulator placed under the chin in a single-incision outpatient procedure, a disposable adhesive sleep wearable that powers the implant nightly, and a patient-facing smartphone app for therapy control and usage tracking. Genio received CE Mark in 2019 and FDA Premarket Approval in August 2025, supported by the DREAM pivotal trial demonstrating a 63.5% AHI responder rate and 70.8% median AHI reduction.

Nyxoah operates a direct enterprise sales model, with a 40-representative US field sales force targeting hospitals and ambulatory surgical centers, complemented by reference accounts in the Netherlands (OLVG West, Zuyderland) and the Middle East (Saudi German Hospital Dubai). The company sells the implantable device and recurring disposable patch consumables, reimbursed under CPT code 64568 with Medicare hospital outpatient payment of approximately $45,000 and ASC payment of $42,373 under the CY2026 rule. Genio is the company's sole commercial product; pricing is not publicly disclosed but the company reports 100% prior-authorization approval on reviewed commercial payer submissions.

Nyxoah is dual-listed on Euronext Brussels (since September 2020) and Nasdaq under ticker NYXH (since July 2021), headquartered in Mont-Saint-Guibert, Belgium with a US office in Summit, New Jersey, and reports 101-250 employees. The company has funded US and international commercialization through multiple public offerings and a €37.5M EIB loan facility, with €36-40M of FY2026 worldwide net revenue guided by management. Strategic investors Cochlear and ResMed participated in a $77M November 2025 financing, and a $110M capital raise (BofA-led $95M equity plus $15M EIB tranche) closed in June 2026. The current CEO, Olivier Taelman, is leading a planned transition to a US-based CEO as the company enters its next US-driven growth phase.

Short descriptiontext

Nyxoah is a Belgian medical device company that develops and commercializes the Genio system, a bilateral hypoglossal nerve stimulation therapy for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP, selling through direct hospital and ASC channels in the US, Europe, and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMont-saint-guibert, Belgium
HQ citystring
Mont-saint-guibert
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurostimulation therapy, sleep apnea treatment, hypoglossal nerve stimulation, implantable medical devices, obstructive sleep apnea devices
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Genio System Sales
TypeHardware Sales
Description

Revenue generated from commercial sales of the Genio hypoglossal nerve stimulation system, including the implantable device and disposable components (wearable patches). The company achieved Q1 2026 global net revenue of €6.4 million with 25% sequential quarterly growth in U.S. net revenue (€4.3 million).

globenewswire.com
2Reimbursement Coverage
TypeHardware Sales
Description

100% prior-authorization approval rate on reviewed commercial payer submissions. Hospital outpatient reimbursement increased by approximately 48% to $45,000 under Medicare CY2026 rule. ASC facility reimbursement increased by 58% to $42,373.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Genio
Description

FDA-approved and CE-Mark validated bilateral neurostimulation therapy system for treating moderate to severe obstructive sleep apnea (OSA).

geniosleep.com
Core offering1 text field

Nyxoah develops and commercializes the Genio system, a leadless, battery-free bilateral hypoglossal nerve stimulation (HGNS) therapy implant for treating moderate to severe obstructive sleep apnea (OSA) in adult patients who have failed, refused, or cannot tolerate CPAP therapy. The system comprises an implantable stimulator placed under the chin in a single-incision outpatient procedure, a disposable external wearable adhesive patch that powers the implant nightly, and a patient-facing smartphone app for therapy control and usage tracking.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 63.5% AHI responder rate in clinical trials
+6 more records
Product overview1 text field

Nyxoah is a medical technology company focused on treating obstructive sleep apnea (OSA). The company's sole product is the Genio System, a comprehensive hypoglossal nerve stimulation therapy consisting of three integrated components: (1) a battery-free implantable neurostimulator that is inserted under the chin in a single-incision outpatient procedure, (2) a disposable sleep wearable patch with external activation chip that powers the implant nightly, and (3) a smartphone app that allows patients to control stimulation within predefined settings and track device usage. Genio received CE Mark approval in 2019 and FDA PMA approval in August 2025 for adult patients with moderate to severe OSA (AHI 15-65) who have not tolerated, failed, or refused CPAP therapy. The therapy works by bilateral stimulation of the hypoglossal nerve to contract tongue muscles and maintain airway patency during sleep.

Product and service1 record
1Genio System
CategoryNeurostimulation Therapy System
Description

A patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy system for treating moderate to severe obstructive sleep apnea (OSA). Includes an implantable battery-free stimulator, a disposable sleep wearable patch with activation chip, and a smartphone app. Designed for adult OSA patients (AHI 15-65) who are not significantly overweight and have not tolerated, failed, or refused CPAP/PAP therapy. The system works through bilateral stimulation of the hypoglossal nerve to keep the airway open during sleep.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Independent reimbursement consulting firm engaged to present on U.S. reimbursement landscape at investor events. Advises on Medicare and commercial payer coverage strategies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers4 records
TypeBroad incumbent
TypeDirect peer
Description

Inspire Medical Systems is the leading U.S. provider of hypoglossal nerve stimulation therapy for OSA with its Inspire UAS system. It is Nyxoah's most direct competitor, addressing the same CPAP-intolerant patient population with an implantable neurostimulator and has multi-year incumbency advantages in U.S. payer coverage and surgeon networks.

TypeBroad incumbent
Description

ResMed is the global leader in sleep-disordered breathing and CPAP therapy. While focused on PAP rather than HGNS, ResMed is a Nyxoah investor and serves the same OSA patient pool, making it both a complementary incumbent and a strategic partner with deep distribution in sleep clinics.

TypeBroad incumbent
Description

Philips is a major player in sleep and respiratory care through its DreamStation and other CPAP/APAP product lines. It operates broadly in the same OSA therapy market, overlapping with Nyxoah on patient population but not on the implantable HGNS modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nyxoah

Neuromodulation Medical Devicesnyxoah.com

Nyxoah is a Belgian medical device company that develops and commercializes the Genio system, a bilateral hypoglossal nerve stimulation therapy for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP, selling through direct hospital and ASC channels in the US, Europe, and the Middle East.

What Nyxoah does

Nyxoah SA is a Belgian medical technology company that develops and commercializes the Genio system, a bilateral hypoglossal nerve stimulation (HGNS) therapy for moderate-to-severe obstructive sleep apnea (OSA) in adults who have failed, refused, or cannot tolerate CPAP. The system consists of a battery-free, leadless implantable neurostimulator placed under the chin in a single-incision outpatient procedure, a disposable adhesive sleep wearable that powers the implant nightly, and a patient-facing smartphone app for therapy control and usage tracking. Genio received CE Mark in 2019 and FDA Premarket Approval in August 2025, supported by the DREAM pivotal trial demonstrating a 63.5% AHI responder rate and 70.8% median AHI reduction.

Nyxoah operates a direct enterprise sales model, with a 40-representative US field sales force targeting hospitals and ambulatory surgical centers, complemented by reference accounts in the Netherlands (OLVG West, Zuyderland) and the Middle East (Saudi German Hospital Dubai). The company sells the implantable device and recurring disposable patch consumables, reimbursed under CPT code 64568 with Medicare hospital outpatient payment of approximately $45,000 and ASC payment of $42,373 under the CY2026 rule. Genio is the company's sole commercial product; pricing is not publicly disclosed but the company reports 100% prior-authorization approval on reviewed commercial payer submissions.

Nyxoah is dual-listed on Euronext Brussels (since September 2020) and Nasdaq under ticker NYXH (since July 2021), headquartered in Mont-Saint-Guibert, Belgium with a US office in Summit, New Jersey, and reports 101-250 employees. The company has funded US and international commercialization through multiple public offerings and a €37.5M EIB loan facility, with €36-40M of FY2026 worldwide net revenue guided by management. Strategic investors Cochlear and ResMed participated in a $77M November 2025 financing, and a $110M capital raise (BofA-led $95M equity plus $15M EIB tranche) closed in June 2026. The current CEO, Olivier Taelman, is leading a planned transition to a US-based CEO as the company enters its next US-driven growth phase.

Nyxoah firmographics

Firmographics
Name
Nyxoah
Legal name
Nyxoah SA
Website
https://nyxoah.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
Nyxoah is a Belgian medical device company that develops and commercializes the Genio system, a bilateral hypoglossal nerve stimulation therapy for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP, selling through direct hospital and ASC channels in the US, Europe, and the Middle East.
Ownership category
akta.pro rank

Nyxoah industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Neurostimulation therapy
  • Sleep apnea treatment
  • Hypoglossal nerve stimulation
  • Implantable medical devices
  • Obstructive sleep apnea devices

Where Nyxoah is headquartered

Location

Headquarters

HQ city
Mont-saint-guibert
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Nyxoah business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Genio System Sales: Revenue generated from commercial sales of the Genio hypoglossal nerve stimulation system, including the implantable device and disposable components (wearable patches). The company achieved Q1 2026 global net revenue of €6.4 million with 25% sequential quarterly growth in U.S. net revenue (€4.3 million).
  2. Reimbursement Coverage: 100% prior-authorization approval rate on reviewed commercial payer submissions. Hospital outpatient reimbursement increased by approximately 48% to $45,000 under Medicare CY2026 rule. ASC facility reimbursement increased by 58% to $42,373.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Nyxoah product offering

Product offering

Core offering

Nyxoah develops and commercializes the Genio system, a leadless, battery-free bilateral hypoglossal nerve stimulation (HGNS) therapy implant for treating moderate to severe obstructive sleep apnea (OSA) in adult patients who have failed, refused, or cannot tolerate CPAP therapy. The system comprises an implantable stimulator placed under the chin in a single-incision outpatient procedure, a disposable external wearable adhesive patch that powers the implant nightly, and a patient-facing smartphone app for therapy control and usage tracking.

Product overview

Nyxoah is a medical technology company focused on treating obstructive sleep apnea (OSA). The company's sole product is the Genio System, a comprehensive hypoglossal nerve stimulation therapy consisting of three integrated components: (1) a battery-free implantable neurostimulator that is inserted under the chin in a single-incision outpatient procedure, (2) a disposable sleep wearable patch with external activation chip that powers the implant nightly, and (3) a smartphone app that allows patients to control stimulation within predefined settings and track device usage. Genio received CE Mark approval in 2019 and FDA PMA approval in August 2025 for adult patients with moderate to severe OSA (AHI 15-65) who have not tolerated, failed, or refused CPAP therapy. The therapy works by bilateral stimulation of the hypoglossal nerve to contract tongue muscles and maintain airway patency during sleep.

Differentiator

Problem solved

Functional benefit

Brands

  • Genio: FDA-approved and CE-Mark validated bilateral neurostimulation therapy system for treating moderate to severe obstructive sleep apnea (OSA).

Products and services

  • Genio System A patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy system for treating moderate to severe obstructive sleep apnea (OSA). Includes an implantable battery-free stimulator, a disposable sleep wearable patch with activation chip, and a smartphone app. Designed for adult OSA patients (AHI 15-65) who are not significantly overweight and have not tolerated, failed, or refused CPAP/PAP therapy. The system works through bilateral stimulation of the hypoglossal nerve to keep the airway open during sleep.

Quantifiable outcome

  • 63.5% AHI responder rate in clinical trials
  • +6 more outcomes

Companies that use Nyxoah

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Nyxoah technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nyxoah partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • JD Lymon GroupcoreImplementation/ SI/ Consulting PartnerIndependent reimbursement consulting firm engaged to present on U.S. reimbursement landscape at investor events. Advises on Medicare and commercial payer coverage strategies.

Scale indicators17 records

Recent moves7 records

Expansion highlights6 records

Nyxoah competitors and assessment

Company assessment

Broad incumbents

  • Fisher & Paykel Healthcare:
  • ResMed: ResMed is the global leader in sleep-disordered breathing and CPAP therapy. While focused on PAP rather than HGNS, ResMed is a Nyxoah investor and serves the same OSA patient pool, making it both a complementary incumbent and a strategic partner with deep distribution in sleep clinics.
  • Koninklijke Philips: Philips is a major player in sleep and respiratory care through its DreamStation and other CPAP/APAP product lines. It operates broadly in the same OSA therapy market, overlapping with Nyxoah on patient population but not on the implantable HGNS modality.

Direct peers

  • Inspire Medical Systems: Inspire Medical Systems is the leading U.S. provider of hypoglossal nerve stimulation therapy for OSA with its Inspire UAS system. It is Nyxoah's most direct competitor, addressing the same CPAP-intolerant patient population with an implantable neurostimulator and has multi-year incumbency advantages in U.S. payer coverage and surgeon networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Nyxoah social profiles

Digital presence

Nyxoah financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nyxoah leadership team

Management profile

Number of profiles

Profiles15 records

Nyxoah funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nyxoah M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nyxoah

What does Nyxoah do?

Nyxoah develops and commercializes the Genio system, a leadless, battery-free bilateral hypoglossal nerve stimulation (HGNS) therapy implant for treating moderate to severe obstructive sleep apnea (OSA) in adult patients who have failed, refused, or cannot tolerate CPAP therapy. The system comprises an implantable stimulator placed under the chin in a single-incision outpatient procedure, a disposable external wearable adhesive patch that powers the implant nightly, and a patient-facing smartphone app for therapy control and usage tracking.

Is Nyxoah a public or private company?

Nyxoah is a public company. It is classified as public and is currently operating.

When was Nyxoah founded?

Nyxoah was founded in 2009. It employs 101 to 250 people.

Where is Nyxoah based?

Nyxoah is headquartered in Mont-saint-guibert, Belgium, in the Europe region.

How does Nyxoah make money?

Two revenue lines are on record. Genio System Sales are the primary driver. The others are reimbursement Coverage.

Who are Nyxoah's main competitors?

Broad incumbents on record are Fisher & Paykel Healthcare, ResMed and Koninklijke Philips. Inspire Medical Systems is listed as a direct peer.

Does Nyxoah have an API?

No public API is recorded for Nyxoah.

What industry is Nyxoah in?

Nyxoah's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialNyxoah Obtains Default Decision Against Inspire Medical Systems In Unified Patent Court CaseThe Unified Patent Court in Munich issued a default decision in favor of Nyxoah against Inspire Medical Systems over European Patent 2 760 534. Nyxoah is considering all enforcement options. The company's Genio system for OSA treatment is also highlighted.YahooNyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court CaseThe Unified Patent Court in Munich issued a default decision in favor of Nyxoah against Inspire Medical Systems over European Patent 2 760 534. Nyxoah is considering all enforcement options. The company also notes its Genio system received FDA approval in August 2025.Stock TitanNyxoah gets default decision in Inspire patent caseNyxoah SA received a default decision in favor of the company from the Unified Patent Court in Munich against Inspire Medical Systems over European Patent 2 760 534. The court ruled in Nyxoah's favor, and the company is considering all enforcement options.GlobeNewswireNyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court CaseThe Unified Patent Court in Munich issued a default decision in favor of Nyxoah against Inspire Medical Systems over European Patent 2 760 534. Nyxoah is considering all enforcement options. The company also noted its Genio system's CE mark and FDA approval.Defense WorldNyxoah (NASDAQ:NYXH) Raised to “Hold” at Wall Street ZenWall Street Zen upgraded Nyxoah from Sell to Hold, while other analysts have mixed ratings. The company reported Q3 EPS of -$0.20, beating estimates of -$0.24, with revenue of $10.39 million. Analysts expect -$1.46 EPS for the current year.BenzingaNyxoah Q3 2026 Earnings Call Transcript - Nyxoah (NASDAQ:NYXH)Nyxoah reported Q3 2026 net revenue of 9.2 million euros, up 19% sequentially, with U.S. revenue at 6.7 million euros, up 29%. The company adjusted its full-year revenue guidance to 33-35 million euros, citing historical ramp patterns. It also highlighted positive AXIS study results and a PMA supplement submission to expand Genio's indication for complete concentric collapse patients.Seeking AlphaRare Stock Picks In October 2026 - From 14 Discerning AnalystsAnalysts with no other bullish recommendations in the past three months issued October 2026 buy picks across healthcare and financials. Femasys, Nyxoah, Harrow, and Peugeot Invest were highlighted, with Femasys and Nyxoah offering over 100% upside and Harrow a 40% upside.American Banking and Market NewsNyxoah SA (NASDAQ:NYXH) Stock Short Interest Report for OctoberNyxoah SA's short interest fell 33.7% to 213,619 shares as of October 15th. The company reported a Q2 loss of $0.67 per share, missing the $0.47 consensus, with revenue of $8.76 million. Analysts have a consensus "Hold" rating with a $3.55 target price.